Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2017

01-01-2017 | Original Article

Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma

Authors: Ji Y. Park, GhilSuk Yoon

Published in: Pathology & Oncology Research | Issue 1/2017

Login to get access

Abstract

Aquaporins (AQP) are transmembrane proteins that provide channels for water and solutes, and some are involved in tumor progression and invasion. We evaluated the expression of AQP-1, AQP-3, and AQP-5 and their clinicopathological significance in prostate adenocarcinomas (PCA). Prostatectomy specimens (n = 99) were retrieved from the surgical pathology archives and clinicopathological data were obtained from the medical database at Kyungpook National University Hospital. Immunohistochemical staining for AQP-1, AQP-3, and AQP-5 was performed on tissue microarrays comprising paired malignant and benign prostatic tissues. Seventeen PCA cases (17.2 %) showed AQP-1 overexpression, specifically 7 tumors (9.7 %) with lower Gleason scores (GS) and 10 tumors (37.0 %) with higher GS, with statistical significance (P = 0.001). AQP-1 overexpression was significantly associated with higher GS (P = 0.001), higher pathologic T (pT) stages (P = 0.024), and biochemical recurrence (BR) (P = 0.002). The difference in AQP-3 and AQP-5 expression between neoplastic and non-neoplastic tissues was not established and there were no correlations with clinicopathological parameters. AQP-1 overexpression was evident in tumors with higher GS, it was less evident in tumors with lower GS, and it was associated with BR and a higher pT stage. AQP-1 overexpression is associated with prostate cancer progression.
Literature
1.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592CrossRefPubMed
2.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882–888CrossRefPubMed
3.
Sales AD, Lobo CH, Carvalho AA, Moura AA, Rodrigues AP (2013) Structure, function, and localization of aquaporins: their possible implications on gamete cryopreservation. Genet Mol Res 12:6718–6732CrossRefPubMed
4.
5.
Yoshida T, Hojo S, Sekine S, Sawada S, Okumura T, Nagata T, Shimada Y, Tsukada K (2013) Expression of aquaporin-1 is a poor prognostic factor for stage II and III colon cancer. Mol Clin Oncol 1:953–958PubMedPubMedCentral
6.
Moon C, Soria JC, Jang SJ, Lee J, Obaidul Hoque M, Sibony M, Trink B, Chang YS, Sidransky D, Mao L (2003) Involvement of aquaporins in colorectal carcinogenesis. Oncogene 22:6699–6703CrossRefPubMed
7.
Otto W, Rubenwolf PC, Burger M, Fritsche HM, Rossler W, May M, Hartmann A, Hofstadter F, Wieland WF, Denzinger S (2012) Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. BMC Cancer 12:459–467CrossRefPubMedPubMedCentral
8.
Machida Y, Ueda Y, Shimasaki M, Sato K, Sagawa M, Katsuda S, Sakuma T (2011) Relationship of aquaporin 1, 3, and 5 expression in lung cancer cells to cellular differentiation, invasive growth, and metastasis potential. Hum Pathol 42(5):669–678CrossRefPubMed
9.
Verkman AS, Hara-Chikuma M, Papadopoulos MC (2008) Aquaporins--new players in cancer biology. J Mol Med (Berl) 86(5):523–529CrossRef
10.
Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434:786–792CrossRefPubMed
11.
Woo J, Lee J, Chae YK, Kim MS, Baek JH, Park JC, Park MJ, Smith IM, Trink B, Ratovitski E, Lee T, Park B, Jang SJ, Soria JC, Califano JA, Sidransky D, Moon C (2008) Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett 264:54–62CrossRefPubMedPubMedCentral
12.
Monzani E, Bazzotti R, Perego C, La Porta CA (2009) AQP1 is not only a water channel: it contributes to cell migration through Lin7/beta-catenin. PLoS One 4(7):e6167CrossRefPubMedPubMedCentral
13.
Aishima S, Kuroda Y, Nishihara Y, Taguchi K, Iguchi T, Taketomi A, Maehara Y, Tsuneyoshi M (2007) Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Hum Pathol 38(12):1819–1825CrossRefPubMed
14.
Yang JH, Shi YF, Chen XD, Qi WJ (2006) The influence of aquaporin-1 and microvessel density on ovarian carcinogenesis and ascites formation. Int J Gynecol Cancer 16(Suppl 1):400–405CrossRefPubMed
15.
Shi Z, Zhang T, Luo L, Zhao H, Cheng J, Xiang J, Zhao C (2012) Aquaporins in human breast cancer: identification and involvement in carcinogenesis of breast cancer. J Surg Oncol 106(3):267–272CrossRefPubMed
16.
Hwang I, Jung SI, Hwang EC, Song SH, Lee HS, Kim SO, Kang TW, Kwon D, Park K (2012) Expression and localization of aquaporins in benign prostate hyperplasia and prostate cancer. Chonnam Med J 48(3):174–178CrossRefPubMedPubMedCentral
17.
Wang J, Tanji N, Sasaki T, Kikugawa T, Song X, Yokoyama M (2008) Androgens upregulate aquaporin 9 expression in the prostate. Int J Urol 15(10):936–941CrossRefPubMed
18.
Pan XY, Guo H, Han J, Hao F, An Y, Xu Y, Xiaokaiti Y, Pan Y, Li XJ (2012) Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol 683:27–34CrossRefPubMed
19.
Wang J, Tanji N, Kikugawa T, Shudou M, Song X, Yokoyama M (2007) Expression of aquaporin 3 in the human prostate. Int J Urol 14:1088–1092CrossRefPubMed
20.
Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66(17):8347–8351CrossRefPubMed
21.
Pirker R, Pereira JR, Pawel J, Krzakowski M, Ramlau R, Park K, Marinis F, Eberhardt W, Paz-Ares L, Storkel S, Schumacher KM, Heydebreck A, Celik I, O’Byrne KJ (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42CrossRefPubMed
22.
23.
Bartholow TL, Becich MJ, Chandran UR, Parwani AV (2011) Immunohistochemical analysis of ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic adenocarcinoma. BMC Urol 11:12–20CrossRefPubMedPubMedCentral
24.
Abascal F, Irisarri I, Zardoya R (2014) Diversity and evolution of membrane intrinsic proteins. Biochim Biophys Acta 1840(5):1468–1481CrossRefPubMed
25.
Tan M, Shao C, Bishop JA, Feng Z, Trock BJ, Westra WH, Ha PK (2014) Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. Otolaryngol Head Neck Surg 150(5):801–807CrossRefPubMedPubMedCentral
26.
King LS, Agre P (1996) Pathophysiology of the aquaporin water channels. Annu Rev Physiol 58:619–648CrossRefPubMed
27.
28.
Hu J, Verkman AS (2006) Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 20(11):1892–1894CrossRefPubMed
29.
Papadopoulos MC, Saadoun S, Verkman AS (2008) Aquaporins and cell migration. Pflugers Arch 456(4):693–700CrossRefPubMed
30.
Shao C, Sun W, Tan M, Glazer CA, Bhan S, Zhong X, Fakhry C, Sharma R, Westra WH, Hoque MO, Moskaluk CA, Sidransky D, Califano JA, Ha PK (2011) Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res 17(13):4320–4330CrossRefPubMedPubMedCentral
31.
Clapp C, Martinez de la Escalera G (2006) Aquaporin-1: a novel promoter of tumor angiogenesis. Trends Endocrinol Metab 17(1):1–2CrossRefPubMed
32.
Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M (2009) Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma. Eur Urol 56(4):690–698CrossRefPubMed
33.
Otterbach F, Callies R, Adamzik M, Kimmig R, Siffert W, Schmid KW, Bankfalvi A (2010) Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. Breast Cancer Res Treat 120(1):67–76CrossRefPubMed
34.
Ribatti D, Ranieri G, Annese T, Nico B (2014) Aquaporins in cancer. Biochim Biophys Acta 1840(5):1550–1553CrossRefPubMed
35.
Liu J, Zhang WY, Ding DG (2015) Expression of aquaporin 1 in bladder uroepithelial cell carcinoma and its relevance to recurrence. Asian Pac J Cancer Prev 16(9):3973–3976CrossRefPubMed
36.
Stigliano C, Aryal S, de Tullio DM, Nicchia G, Pascazio G, Svelto M, Decuzzi P (2013) siRNA-chitosan complexes in poly(lactic-co-glycolic acid) nanoparticles for the silencing of aquaporin-1 in cancer cells. Mol Pharm 10(8):3186–3194CrossRefPubMed
37.
Bin K, Shi-Peng Z (2011) Acetazolamide inhibits aquaporin-1 expression and colon cancer xenograft tumor growth. Hepatogastroenterology 58:1502–1506CrossRefPubMed
38.
Chae YK, Woo J, Kim MJ, Kang SK, Kim MS, Lee J, Lee SK, Gong G, Kim YH, Soria JC, Jang SJ, Sidransky D, Moon C (2008) Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One 3(5):e2162CrossRefPubMedPubMedCentral
Metadata
Title
Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma
Authors
Ji Y. Park
GhilSuk Yoon
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0145-7

Other articles of this Issue 1/2017

Pathology & Oncology Research 1/2017 Go to the issue

Original Article

Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability

Original Article

Frameshift Mutations in the Mononucleotide Repeats of TAF1 and TAF1L Genes in Gastric and Colorectal Cancers with Regional Heterogeneity

Original Article

Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia

Original Article

Negative Regulatory Role of TWIST1 on SNAIL Gene Expression

Original Article

Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo

Original Article

Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits